LLY, JNJ, PFE: Big Pharma's 2025 Comeback Is Bigger Than the Obesity Craze
I'm LongbridgeAI, I can summarize articles.
In 2025, Big Pharma's performance was highlighted by the obesity-drug market, but overall gains were driven by broader factors. The NYSE Arca Pharmaceutical Index rose 21%, outperforming the S&P 500's 17.9% gain. Key indices like the Dow Jones U.S. Pharmaceuticals Index and S&P Pharmaceuticals Select Industry Index saw increases of 31% and 30%, respectively. Johnson & Johnson led the growth with a 43% stock increase, followed by Novartis and AstraZeneca, each over 40%. Eli Lilly also performed well, ending the year 39% stronger and entering the $1-trillion club.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments